ClinicalTrials.gg

Program

Ivermectin

Also written as “ivermectin”, “Ivermectin cream” and “CD5024”.

Its studies are mostly in Rosacea · COVID-19 · Lice Infestations · Dermatitis, Atopic · Acne Vulgaris, led by 14 companies.

Furthest: phase 4, since Nov 24, 201528 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Galderma Group60 open or runningphase 4since Nov 24, 2015Dec 14, 2011none ahead
Johnson & Johnson40 open or runningphase 3since Jan 8, 2009Jan 8, 2009none ahead
Topaz Pharmaceuticals40 open or runningphase 3since Feb 8, 2010Oct 1, 2009none ahead
Humanis Saglık Anonim Sirketi20 open or runningphase 1since Sep 13, 2021Sep 13, 2021none ahead
MedinCell S.A20 open or runningphase 2since Mar 28, 2022Oct 26, 2020none ahead
Sun Pharmaceutical Industries20 open or runningphase 1since May 3, 2017May 3, 2017none ahead
Genuine Research Center, Egypt10 open or runningphase 1since Apr 18, 2021Apr 18, 2021none ahead
Infectopharm Arzneimittel10 open or runningphase 3since Sep 28, 2021Sep 28, 2021none ahead
Insud Pharma10 open or runningphase 3since Aug 8, 2023Aug 8, 2023none ahead
mayne-pharma-international-pty-ltd10 open or runningphase 3since Oct 30, 2017Oct 30, 2017none ahead
Padagis10 open or runningphase 3since Jun 6, 2016Jun 6, 2016none ahead
Teva Pharmaceutical Industries10 open or runningphase 3since Jul 19, 2016Jul 19, 2016none ahead
united-laboratories10 open or runningphase 2since Sep 14, 2017Sep 14, 2017none ahead
Zydus Lifesciences10 open or runningphase 3since Sep 25, 2019Sep 25, 2019none ahead

Also a collaborator on its studies: eva-pharma and biorasi-llc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 14 studies since Jan 8, 2009.

  1. Nov 21, 2016Phase 2 study in Acne VulgarisGalderma Group · NCT03034460 · 70 enrolled · Canada, France, Germany
  2. May 3, 2017Sun Pharmaceutical Industries's first study: phase 1 study in Lice InfestationsNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT03257943 · 413 enrolled · United States
  3. Aug 11, 2017Phase 2 study in Dermatitis, AtopicGalderma Group · NCT03250624 · 63 enrolled · Canada
  4. Sep 14, 2017united-laboratories's first study: phase 2 study in Pediculosis CapitisNew to united-laboratoriesunited-laboratories · NCT03286101 · 120 enrolled · Philippines
  5. Oct 30, 2017mayne-pharma-international-pty-ltd's first study: phase 3 study in Head LiceNew to mayne-pharma-international-pty-ltdmayne-pharma-international-pty-ltd · NCT03337490 · 296 enrolled · United States
  6. Sep 25, 2019Zydus Lifesciences's first study: phase 3 study in Facial RosaceaNew to Zydus LifesciencesZydus Lifesciences · NCT04106726 · 525 enrolled · United States
  7. Oct 26, 2020MedinCell S.A's first study: phase 1 study in COVID-19New to MedinCell S.AMedinCell S.A · NCT04632706 · 24 enrolled · United Kingdom
  8. Apr 18, 2021Genuine Research Center, Egypt's first study: phase 1 study in HealthyNew to Genuine Research Center, EgyptGenuine Research Center, Egypt · NCT04854460 · 30 enrolled · Egypt
  9. Sep 13, 2021Humanis Saglık Anonim Sirketi's first study: phase 1 study in Anthelmintic AgentNew to Humanis Saglık Anonim SirketiHumanis Saglık Anonim Sirketi · NCT05082753 · 50 enrolled · Jordan
  10. Sep 28, 2021Infectopharm Arzneimittel's first study: phase 3 study in COVID-19New to Infectopharm ArzneimittelInfectopharm Arzneimittel · NCT05060666 · 412 enrolled
  11. Mar 28, 2022Phase 2 study in COVID-19MedinCell S.A · NCT05305560 · 400 enrolled · Bulgaria
  12. Aug 8, 2023Insud Pharma's first study: phase 3 study in COVID-19New to Insud PharmaInsud Pharma · NCT05993143 · 249 enrolled · Spain
  13. Aug 14, 2024Phase 1 study in RosaceaHumanis Saglık Anonim Sirketi · NCT06557603 · 44 enrolled · India
  14. Aug 26, 2026Phase 1 study in RosaceaSun Pharmaceutical Industries · NCT07795567 · 865 enrolled · United States

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Glutamate-gated chloride channel modulator; Glutamate-gated chloride channel modulator”ChEMBL 37, by rule

Studies

All 28 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07795567Rosacea · United States1CompletedSun Pharmaceutical IndustriesJun 24, 2026865
NCT06557603Rosacea · India1CompletedHumanis Saglık Anonim SirketiJul 11, 202444
NCT05993143COVID-19 · Spain3TerminatedInsud PharmaJul 21, 2021249
NCT05305560COVID-19 · Bulgaria2CompletedMedinCell S.ASep 15, 2022400
NCT05060666COVID-193UNKNOWNInfectopharm ArzneimittelMar 2022412
NCT05082753Anthelmintic Agent · Jordan1CompletedHumanis Saglık Anonim SirketiDec 21, 202050
NCT04854460Healthy · Egypt1CompletedGenuine Research Center, EgyptFeb 25, 202130
NCT04632706COVID-19 · United Kingdom1CompletedMedinCell S.AMar 9, 202124
NCT04106726Facial Rosacea · United States3CompletedZydus LifesciencesAug 4, 2020525
NCT03337490Head Lice · United States3Completedmayne-pharma-international-pty-ltdDec 4, 2017296
NCT03286101Pediculosis Capitis · Philippines2Completedunited-laboratoriesOct 12, 2017120
NCT03250624Dermatitis, Atopic · Canada2CompletedGalderma GroupJun 26, 201763
NCT03257943Lice Infestations · United States1CompletedSun Pharmaceutical IndustriesJun 27, 2017413
NCT03034460Acne Vulgaris · Canada, France, Germany2CompletedGalderma GroupNov 2, 201670
NCT02840461Moderate to Severe Papulopustular Rosacea · United States3CompletedTeva Pharmaceutical IndustriesNov 2016630
NCT02795117Rosacea3CompletedPadagisFeb 2017486
NCT02616250Rosacea · United States, Canada4CompletedGalderma GroupSep 2016190
NCT01493947Rosacea · Bulgaria, Czech Republic, France and more3CompletedGalderma GroupDec 2013962
NCT01494467Rosacea · United States, Canada3CompletedGalderma GroupAug 2013688
NCT01493687Rosacea · United States, Canada3CompletedGalderma GroupJul 2013683
NCT01068158Head Lice · United States3CompletedTopaz PharmaceuticalsJun 2010371
NCT01066585Head Lice · United States3CompletedTopaz PharmaceuticalsJun 2010410
NCT00994422Head Lice · United States2CompletedTopaz PharmaceuticalsDec 2009264
NCT00988533Head Lice · United States1CompletedTopaz PharmaceuticalsNov 200930
NCT00921674Healthy1CompletedJohnson & JohnsonApr 200524
NCT00921219Healthy1CompletedJohnson & JohnsonNov 200534
NCT00921154Fasting · Ireland1CompletedJohnson & JohnsonMay 200524
NCT00819520Lice Infestations · France, Ireland, Israel and more3CompletedJohnson & JohnsonSep 2004812

How it is read

Names in the registry

  • “Ivermectin”, 4 entries
  • “ivermectin”, 4 entries
  • “Ivermectin cream”, 2 entries
  • “CD5024”, 2 entries
  • “0.5% Ivermectin Cream”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.